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Streptozotocin Stimulates the Ion Channel TRPA1 Directly
INVOLVEMENTOF PEROXYNITRITE*
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Background: Streptozotocin produces diabetes and diabetic neuropathy in experimental animals.
Results: Streptozotocin stimulates TRPA1 through oxidation of cysteine residues, which leads to acute sensory changes in vivo.
Conclusion: Cysteine oxidation is a novel mechanism of action for streptozotocin.
Significance: The diabetogenic agent streptozotocin induces acute sensory changes prior to the onset of diabetes.
Streptozotocin (STZ)-induceddiabetes is themost commonly
used animalmodel of diabetes.Here,wehavedemonstrated that
intraplantar injections of low dose STZ evoked acute polymodal
hypersensitivities in mice. These hypersensitivities were inhib-
ited by a TRPA1 antagonist and were absent in TRPA1-null
mice. In wild type mice, systemic STZ treatment (180 mg/kg)
evoked a loss of cold and mechanical sensitivity within an hour
of injection, which lasted for at least 10 days. In contrast,
Trpa1/mice developedmechanical, cold, and heat hypersen-
sitivity 24 h after STZ. The TRPA1-dependent sensory loss pro-
duced by STZ occurs before the onset of diabetes and may thus
not be readily distinguished from the similar sensory abnormal-
ities produced by the ensuing diabetic neuropathy. In vitro, STZ
activated TRPA1 in isolated sensory neurons, TRPA1 cell lines,
and membrane patches. Mass spectrometry studies revealed
that STZ oxidizes TRPA1 cysteines to disulfides and sulfenic
acids. Furthermore, incubation of tyrosine with STZ resulted in
formation of dityrosine, suggesting formation of peroxynitrite.
Functional analysis ofTRPA1mutants showed that cysteine res-
idues that were oxidized by STZ were important for TRPA1
responsiveness to STZ. Our results have identified oxidation of
TRPA1 cysteine residues,most likely by peroxynitrite, as a novel
mechanism of action of STZ. Direct stimulation of TRPA1 com-
plicates the interpretation of results from STZ models of dia-
betic sensory neuropathy and strongly argues that more refined
models of diabetic neuropathy should replace the use of STZ.
Diabetes induced by administration of streptozotocin (STZ)3
has long been the most widely used rodent model for studies of
diabetes and diabetic complications. Sensory neuropathy is one
of the most common and serious long term complications of
diabetes, and the prevalence of diabetic neuropathy is rising
with the global increase in type 2 diabetes (1, 2). Pain and loss of
sensation aremajor symptoms associatedwith diabetic neurop-
athy and constitute an immense burden to patients and society
(1, 3). Pain is an early manifestation of neuropathy in both type
1 and type 2 diabetic patients, with about half of patients expe-
riencing pain particularly during the early stages when they
suffer from a range of symptoms, including burning and shoot-
ing pains and aches initially in the distal limbs (4). Although loss
of sensitivity is themost commonmanifestation of sensory neu-
ropathy, some patients also experience hypersensitivities to
mechanical (pressure and light touch) and thermal (cold/heat)
stimuli. In rodent studies of STZ-induced diabetic neuropathy,
rats typically display mechanical and thermal hyperalgesia,
whereas mice develop mechanical and thermal hypoalgesia (5).
The lack of understanding of the pathogenesis of diabetic neu-
ropathy and pain has hampered the development of mecha-
nism-based therapies. The major current treatments target the
management of painwith anti-convulsant, anti-depressant, and
opioid drugs that often have limited efficacy or unacceptable
side effects (4).
The ion channel TRPA1 is expressed in a subset of nocicep-
tive sensory neuronswhere it acts as a promiscuous receptor for
oxidants and electrophilic agents, but it is also activated by a
number of nonreactive compounds (6). Covalent modification
of cysteine residues present in the intracellular N terminus of
TRPA1 is thought to underlie the agonist activity of oxidants
and electrophilic agonists (7, 8). Several inflammatory media-
tors and transmitters sensitize or activate TRPA1 indirectly
through G-protein-coupled receptors (9, 10). Studies with
RNAi knockdown or pharmacological inhibitors have shown
that TRPA1 plays an important role in the development of
mechanical and cold hyperalgesia in models of inflammatory
and neuropathic pain (11–13). TRPA1 has attracted interest for
its potential role in painful diabetic neuropathy, because inhi-
bition of TRPA1 prevents development of mechanical hyperal-
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Award BDA 13/0004649 (to D. A. A. and S. B.).
1 To whom correspondence should be addressed. Tel.: 44(0)2078486141;
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3 The abbreviations used are: STZ, streptozotocin; DRG, dorsal root ganglion;
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gesia in the STZ rat model of diabetes (14, 15). In addition, the
glucose metabolite methylglyoxal and several other electro-
philic, harmful metabolites formed during hyperglycemia are
endogenous TRPA1 agonists (16–18) and may be responsible
for hyperalgesia in diabetic neuropathy (19).
Here, we have examined the sensory effects of topical and sys-
temic STZ treatment before theonset of diabetes and thedevelop-
ment of diabetic neuropathy. We noticed that topical STZ pro-
ducedarapidproalgesiceffect,whereas systemicadministrationof
STZ evoked a loss of mechanical and cold sensitivity within an
hour of injection. We have identified TRPA1 as the target for the
pronociceptive actions of STZ.UsingTRPA1-expressing cell lines
and cultured sensory neurons, we demonstrate that STZ stimu-
lates TRPA1 directly. Finally, we show that STZ decomposition
generates peroxynitrite, which oxidizes TRPA1 cysteine residues
found in theTRPA1N terminus, in good agreementwith our cur-
rent understanding of howoxidants and electrophilic compounds
activate TRPA1.
Materials andMethods
Behavioral Experiments—Animal studies were performed
according to the UK Home Office Animal Procedures Act
(1986) after in-house ethical review. C57BL/6J mice were
obtained from Harlan UK Ltd., and Trpa1/ mice were bred
from heterozygous mice kindly provided by Drs. Kelvin Kwan
and David Corey (Harvard Medical School, Boston) (20). The
mice were backcrossed onto the C57Bl/6J background for 10
generations prior to this set of experiments. The TRPA1 antag-
onistAP18was prepared in PBS containing 1%DMSOand 0.5%
Tween 80 and administered by either intraperitoneal (2.5
mg/kg in 0.3 ml) or intraplantar (5 g in 25 l) injections. STZ
stock solutions were prepared in 0.1 mM citric acid (pH 4.5) and
adjusted to pH7.4 (NaHCO3) just before administration. STZwas
administered by intraplantar (1–100 g in 25 l) or intraperito-
neal (180 mg/kg in 0.2 ml) injections. Blood glucose levels were
monitored using a Contour XT blood glucose meter (Bayer
Healthcare).Beforenociceptive testing, themicewerekept in their
holding cages to acclimatize (10–15 min) to the experimental
room. Thermal sensitivity was assessed using a commercially
available hot and cold plate (Ugo Basile, Milan, Italy), by placing a
hind paw of a lightly restrained mouse onto the plate surface and
measuring the latency to paw withdrawal as described previously
(21). Pawwithdrawal latencies were determinedwith the plate set
at a chosen temperature (50 °C for hot plate and 10 °C for cold
plate tests).Mechanical sensitivitywas assessed bymeasuring paw
withdrawal thresholds to an increasing mechanical force applied
to the dorsal surface of the paw using an Analgesymeter (Ugo-
Basile). The nociceptive threshold was defined as the force in
gramsatwhich themousewithdrewitspaw.Toavoid tissue injury,
the maximum force applied was set to 150 g.
Cell Culture—DRG neurons were prepared from adult male
or female Trpa1/ and Trpa1/ C57Bl/6J mice using meth-
ods described previously (22). Isolated neurons were plated on
poly-D-lysine-coated coverslips and maintained at 37 °C in an
atmosphere of 95% air, 5%CO2 inMEMAQ(containing 5.6mM
glucose, Sigma, Poole, UK) supplementedwith 10% fetal bovine
serum, 100 units/ml penicillin, 100g/ml streptomycin, and 50
ng/ml NGF (Promega, Southampton, UK) and used for exper-
imentation within 48 h. Untransfected CHO cells and CHO
cells expressing mouse TRPA1 were grown in MEM AQ sup-
plemented with penicillin (100 units/ml), streptomycin (100
g/ml), FCS (10%), and hygromycin (200 g/ml). TRPA1
expression was under the control of a tetracycline-inducible
promoter, and expression was induced by addition of tetracy-
cline before experimentation (23). HEK 293t cells were trans-
fected with plasmids of hTRPA1 or mutant hTRPA1 (1 g
each) using Nanofectin (PAA, Pasching, Austria). 24 h after
transfection, cells were plated onto poly-L-lysine-coated cover-
slips and used for calcium imaging experiments the same day.
Human TRPA1 cDNA and cDNA of a mutant hTRPA1 lacking
cysteine residues with or without lysine 710 in the intracellular
domain (C621S/C641S/C665SK710R) were the kind gift
from Dr. Sven-Eric Jordt (Department of Pharmacology, Yale
University, New Haven, CT). For some experiments, HEK 293t
cells stably expressing hTRPA1 were used.
[Ca2]i Measurements—CHO, HEK 293t cells, and DRG
neurons were loaded with 2.5–3M Fura-2 AM in the presence
(CHOandDRG) or absence (HEK 293t) of 1mMprobenecid for
45–60 min in a physiological saline solution containing (in
millimolars) either 140 NaCl, 5 KCl, 10 glucose, 10 HEPES, 2
CaCl2, and 1 MgCl2, buffered to pH 7.4 (NaOH) or NaCl 145,
KCl 5, CaCl2 1.25, MgCl2 1, glucose 10, HEPES 10. Images of
groups of cells were captured every 1 or 2 s at 340 and 380 nm
excitation wavelengths with emission measured at 520 nm
with a microscope-based imaging system (either PTI, New Jer-
sey, or Visitron Systems GmbH, Puchheim, Germany). Analy-
ses of emission intensity ratios at 340/380 nm excitation (R, in
individual cells) were performedwith ImageMaster orVisiView
2.1.1 software. In experiments on HEK cells, the background
fluorescence was subtracted before calculation of ratios; cells
were stimulated with 250 M carvacrol to functionally identify
transfected cells, and 5 M ionomycin was applied as a control
at the end of each experiment. Averaged results are reported as
means ( S.E.) of area under the curve ( ratio F340/380 nm).
Electrophysiology—CHO cells and DRG neurons were stud-
ied under voltage clamp conditions using an Axopatch 200B
amplifier and pClamp 10.0 software (Axon Instruments). Boro-
silicate glass pipettes (3–6 megohms, 75–80% series resistance
compensation) were filled with (in millimolars) 140 KCl (CHO
cells) or CsCl (DRG neurons), 1 CaCl2, 2 MgATP, 10 EGTA,
and 10HEPES (pH 7.4withKOHorCsOHas appropriate). The
physiological saline solution detailed for the Ca2 measure-
ments above was used extracellularly. Cells studied under
Ca2-free conditionswere superfusedwith (inmillimolars) 140
NaCl, 5KCl, 1 MgCl2, 1 EGTA, 10 HEPES, and 10 glucose (pH
7.4, NaOH), and the pipettes were filled with 140 KCl, 2
MgATP, 5 1,2-bis(2-aminophenoxy)ethane-N,N,N,N-tetra-
acetic acid, and 10 HEPES (pH 7.4, KOH). Inside-out patches
were recorded with (in millimolars) 140 NaCl, 1 MgCl2, 1
EGTA, 10 HEPES (pH 7.4, NaOH) in the pipette. The intracel-
lular face of the patch was superfused with (in millimolars) 140
KCl, 2 MgATP, 1 EGTA, and 10 HEPES (pH 7.4, KOH). Strep-
tozotocinwas diluted as late as possible, usually after a giga-seal
had been established. HEK 293t cells were recorded using an
EPC10 HEKA amplifier (HEKA Elektronik, Lamprecht, Ger-
many). Pipettes were filled with (in millimolars) KCl 140,
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MgCl2 2, EGTA5,HEPES 10 (pH 7.4 with KOH), and the exter-
nal solution contained (in millimolars) NaCl 140, KCl 5, MgCl2
2, CaCl2 2, HEPES 10, and glucose 10 (pH 7.4 with tetrameth-
ylammonium hydroxide).
Mass Spectrometry—A model peptide of the intracellular
N-terminal sequence of hTRPA1 comprising amino acids 607–
670 (UniProt database, O75762; Thermo Fisher Scientific,
Schwerte, Germany) was synthesized. Ultra high resolution
ESI-TOF mass spectrometry was performed on a maXis mass
spectrometer (Bruker Daltonics, Bremen, Germany) on 50 M
peptide in 20 mM ammonium bicarbonate buffer (pH 7.4) that
was treated with 500 M STZ for 75 min. Additionally, one set
of samples was incubated with STZ and 1 mM dimedone for 75
min.Afterthetreatment,sampleswereincubatedwithiodoacet-
amide (45 min at 50 °C), mixed with acetonitrile (1:1, v/v), and
0.1% formic acid and sprayed directly into the ion source. The
instrumental parameters were as follows: injection rate 180
l/h; source temperature 320 °C; capillary voltage 4.5 kV; and
collision voltage 10 kV. All experiments were carried out in the
positive ionmode, and the obtained spectra were deconvoluted
and further processed in data analysis software provided by
Bruker Daltonics. For the time-resolvedMS, STZ was added to
20 mM ammonium carbonate buffer (pH 7.4), and the spectra
were continuously monitored during 45 min.
Cysteine Oxidation, Dihydrorhodamine 123 Oxidation, and
Dityrosine Formation—The effect of STZ on cysteine oxidation
was assessed by Ellman’s reaction, whereas the effects on di-
hydrorhodamine oxidation and dityrosine formation were
studied by following the characteristic emissionwavelengths, as
described previously (24).
Measurement of TRPA1Disulfide Formation inVivo—Dorsal
root ganglia were dissected before and 1 and 24 h after STZ
injection (180 mg/kg) mice. Ganglia from two animals were
pooled together and lysed in N-ethylmaleimide-containing
buffer, and TRPA1 was purified by immunoprecipitation (25).
The protein was then treated with DTT, desalted on a BioSpin
column, and treated with Cy3-N-ethylmaleimide. The samples
were run on gradient gels, and the band was visualized by using
a ChemiDocTM MP System (Bio-Rad).
Drugs and Chemicals—Fura-2 AM was from Life Technolo-
gies, Inc., and dissolved in DMSO with 10% pluronic acid (Life
Technologies, Inc.). MnTM-PyP-CL5 was provided by M. R.
Filipovic. AP18 was from Maybridge (Tintagel, Cornwall, UK)
and HC030031 from TOSLab (Ekaterinburg, Russia). Strepto-
zotocin, salts, and all other reagents were from Sigma. STZ
stock solutions were prepared in 0.1 mM citrate (pH 4.5) and
adjusted to pH 7.4 just before administration. AP18 was dis-
solved in 1% DMSO, 0.5% Tween 80, in 0.9% saline for behav-
ioral experiments and in DMSO for cellular assays.
Statistics—Differences in cellular and behavioral response
amplitudes, thresholds, and latencieswere analyzedbyStudent’s t
test, Mann-Whitney U test, or analysis of variance followed by
Tukey’s HSD test.
Results
Nociceptive Effects of Streptozotocin—We initially performed
a dose-response experiment with intraplantar (i.pl.) injections
of STZ (1–100 g in 25 l) in C57Bl/6J mice to determine
whether STZ exerts a local effect on sensory function in vivo.
The sensitivities to mechanical (paw pressure test) and cold
stimulation (cold plate)weremonitored for 24 h after injections
to establish the time course of any effects. Intraplantar STZ
rapidly exerted a pronociceptive effect and reduced the
mechanical withdrawal threshold significantly at each exam-
ined dose, whereas vehicle administration was without effect
(Fig. 1A). The mechanical hypersensitivity was evident within
30min of administration and showed no sign of reversal within
6 h, but after 24 h, the paw withdrawal thresholds had returned
to the naive, preinjection levels. STZ (1–100g, i.pl.) produced
a similar but less pronounced reduction in the paw-withdrawal
latency in the cold plate test, with a somewhat delayed onset
compared with the mechanical hypersensitivity (Fig. 1B).
TRPA1mediates cellular and behavioral responses to stimu-
lation with a number of oxidants and electrophilic chemicals
(20, 26). In vivo, activation of TRPA1 by locally administered
agonists evokes a mechanical hyperalgesia and cold hypersen-
sitivity (20, 27) similar to that observed here following local
injections of STZ. To determine whether TRPA1 was respon-
sible for the pronociceptive effect of STZ, we examined the
effect of the selective TRPA1 antagonist AP18 (12). Intraperi-
toneal injections of AP18 (2.5 mg/kg, 5 h after 1 g i.pl. STZ)
completely inhibited the STZ-induced reduction in paw with-
FIGURE 1. STZ is pronociceptive. Intraplantar injections of STZ reduced the
pawpressure testwithdrawal threshold (A) andcold-platewithdrawal latency
(B) inmice (n	6).C,effect of STZ (1g, i.pl.) on thepawwithdrawal threshold
in mice, measured 30 min after administration of AP18 (2.5 mg/kg i.p., red
columns) or vehicle (black columns). AP18 or vehicle was administered 5 h
after STZ (n	 3). D, local intraplantar AP18 (5 g) inhibited the STZ-evoked
mechanical hyperalgesia when co-administeredwith 1g of STZ (n	 6). STZ
(1g) evokedmechanical (E) and heat (F) hyperalgesia inwild type but not in
Trpa1/mice (n	 6). Data aremean S.E. of the indicated number ofmice;
*, p
 0.05; **, p
 0.01; ***, p
 0.001 compared with vehicle (veh), Tukey’s
HSD test, or t test (C)).
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drawal threshold (Fig. 1C). Furthermore, i.pl. co-injection of
AP18 (5 g) together with STZ (1 g) prevented the develop-
ment of mechanical hyperalgesia for at least 3 h, demonstrating
that AP18 and STZ act locally in the paw (Fig. 1D). At later time
points when AP18 is likely to have been cleared from the tissue
(12), mechanical hyperalgesia developed to a similar level to
that observed in the vehicle-treated STZ group.
We next examined the effect of i.pl. injections of STZ (1 g)
in Trpa1/ and Trpa1/ mice. STZ produced the expected
pronounced mechanical hyperalgesia in wild type mice (Fig.
1E). In contrast, STZ was without any effect on the paw with-
drawal threshold in Trpa1/ mice, suggesting an obligatory
role for TRPA1 in the acute STZ-evoked hyperalgesia (Fig. 1E),
consistent with the inhibitory effects of AP18 noted above.
TRPA1 is primarily expressed in TRPV1-positive, heat-sensi-
tive nociceptive neurons, but it is not involved in the transduc-
tion of heat, either in vivo or in vitro. Nevertheless, TRPA1
activation in vivo elicits thermal hyperalgesia (26, 28) in addi-
tion to mechanical and cold hypersensitivity (20, 27). Although
the baseline sensitivity to noxious mechanical and cold stimu-
lation is reduced in Trpa1/ mice (Fig. 1E) (20, 26–28), they
display normal sensitivity to noxious heat. Sensitivity to nox-
ious heat therefore provides an ideal test to assess involvement
of TRPA1 in the absence of phenotypic differences between
naive Trpa1/ and Trpa1/mice. In the hot plate test, local
administration of STZ (1 g i.pl.) reduced the paw withdrawal
latency significantly in wild type mice but was without any
effect on the latency in TRPA1-null mice (Fig. 1F), demonstrat-
ing that TRPA1 is necessary for STZ-mediated induction of
acute thermal hyperalgesia.
Systemic STZ Produces Acute Sensory Loss—We next exam-
ined the effect of a larger systemic dose of STZ (180 mg/kg,
intraperitoneal injection), commonly used to induce diabetes in
mice. We first monitored blood glucose levels of wild type and
Trpa1/ mice injected intraperitoneally with STZ (180
mg/kg) to determine whether TRPA1 influenced STZ-medi-
ated induction of diabetes (29). STZ (180 mg/kg) induced
hyperglycemia of similar severity, onset, and duration in mice
of the two genotypes (Fig. 2A). When the early phase of induc-
tion was monitored closely, it was clear that hyperglycemia
developed around 3 days after STZ administration in both wild
type and Trpa1/ mice (Fig. 2B). In parallel experiments, we
monitored the nociceptive thresholds in mice after STZ injec-
tions (180 mg/kg, intraperitoneal). Strikingly, the paw pressure
withdrawal threshold was significantly increased in wild type
mice within 1 h, and this reduced sensitivity wasmaintained for
at least 10 days (Fig. 2C). In wild typemice, we noticed a similar
rapid loss of sensation to stimulation with noxious cold, which
lasted for at least 10 days (Fig. 2D). In contrast, the sensitivity to
noxious heat was not altered significantly by STZ in wild type
mice during the 10-day observation period (Fig. 2E).
Naive Trpa1/ mice display a marked loss of mechanical
and cold sensitivities, as demonstrated previously (Fig. 1E) (20,
21, 27, 28), but normal sensitivity to noxious heat (Fig. 2, C–E).
In contrast to our observations in wild type mice, intraperito-
neal administration of STZ (180 mg/kg) did not alter the
mechanical or cold sensitivity and similarly had no significant
effect on heat sensitivity after 1 h in Trpa1/mice. However,
at later time points, an STZ-mediated significant hypersensitiv-
ity developed in Trpa1/mice in all three tests (Fig. 2, C–E).
These results demonstrated that the systemic dose of STZ used
to induce diabetes in mice produces sensory abnormalities
through multiple mechanisms during the first 24 h after in-
jection. Importantly, our findings demonstrate that TRPA1 is
required for the pronounced earlymechanical and cold hypoalge-
sia seen in wild typemice after systemic administration of STZ.
Streptozotocin Is a TRPA1 Agonist—The observation that
TRPA1 is required for the acute nociceptive effects produced
by topical STZ prompted us to examine whether STZ stimu-
lates TRPA1 directly. In these experiments we used Fura-2
to monitor changes in intracellular calcium concentration
([Ca2]i) in culturedDRGneurons and inCHOcells expressing
mouse TRPA1. STZ evoked [Ca2]i increases with an EC50 of
150 M in CHO cells expressing TRPA1 (Fig. 3A), but it was
without effect on the [Ca2]i in untransfected CHO cells (data
not shown). In cultured DRG neurons, STZ elicited concen-
FIGURE 2. Systemic STZ treatment evokes TRPA1-dependent hypoalge-
sia. A, intraperitoneal injections of STZ (180mg/kg) induce hyperglycemia of
similar severity and duration in Trpa1/ and Trpa1/ mice. B, early time
course of STZ-evoked hyperglycemia is similar in wild type and Trpa1/
mice. Hyperglycemia is established about 3 days after STZ administration.
Within1hof STZ (180mg/kg) injection,wild typemicedevelopedmechanical
(C) and cold (D) hyposensitivity, which lasted for at least 10 days. STZ
increased the sensitivity to cold andmechanical stimulation in Trpa1/mice
after 24 h. E, STZ was without effect on the sensitivity to noxious heat in wild
type mice but elicited a progressive thermal hyperalgesia in Trpa1/mice.
Data are mean S.E. of n	 4–8; **, p
 0.01; ***, p
 0.001 compared with
preinjection value; †††, p
 0.001 comparedwithwild type, Tukey’s HSD test.
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tration-dependent [Ca2]i responses in a subpopulation
of neurons with an EC50 value of 140 M, almost identical to
that produced in TRPA1 CHO cells (Fig. 3B). Pharmacological
inhibition of TRPA1 (AP18 20 M) reduced the proportion of
DRG neurons responding to STZ (1 mM) from 22% of DRG
neurons (213 of 956 neurons examined) to 5% (22 of 414 neu-
rons). Finally, we examined the effect of STZ (500 M) on DRG
neurons cultured from Trpa1/ and Trpa1/ mice. As
TRPA1 is mainly present in TRPV1-expressing, capsaicin-sen-
sitive DRG neurons (23, 30), we restricted the analysis to these
neurons. STZ stimulated [Ca2]i responses in 41% (139 of 341)
of capsaicin-sensitive DRG neurons in cultures from Trpa1/
mice (Fig. 3C), but it failed to produce any [Ca2]i responses (0
of 257) in these neurons isolated fromTrpa1/mice (Fig. 3D).
From these experiments, we conclude that TRPA1 mediates
STZ responses in DRG neurons as well as the acute pronocice-
ptive effect produced by STZ in vivo.
In voltage clamp experiments, application of STZ evoked
inwardwhole-cell currents inmTRPA1CHOcells (Fig. 3E) and
in AITC-sensitive, cultured DRG neurons (Fig. 3F), consistent
with activation of TRPA1. Furthermore, recordings from
inside-out membrane patches excised from mTRPA1 CHO
cells demonstrated that STZ stimulated single channel activity
by a membrane-delimited mechanism (Fig. 3G). STZ-evoked
TRPA1 currents were completely and reversibly inhibited by
co-application of the selective TRPA1 antagonist HC030031
(50 M; Fig. 3, H and I).
Covalent Modification of N-terminal Cysteine Residues in
TRPA1—Oxidants and electrophilic agonists are thought to
stimulate TRPA1 through covalent modification of cysteine
residues located in the intracellular N terminus (7, 8, 31). To
investigate the importance of these N-terminal cysteine resi-
dues in streptozotocin-induced activation of TRPA1, a custom-
made synthetic peptide consisting of 64 amino acids of the
human TRPA1 channel orthologue (residues 607–670) was
used. This peptide contained three essential cysteine residues
(Cys-621, Cys-641, and Cys-665) as well as three additional
neighboring cysteines, all of which are conserved in the mouse
TRPA1 channel. The peptide was treated with 10-fold molar
excess of STZ for 75min, then incubated with 50-fold excess of
iodoacetamide (IA), and analyzed by HPLC-ESI-TOF-MS. The
control untreated peptide showed only one species with a
monoisotopic peak atm/z 8003.5, which corresponds tomolec-
ular weight of the peptide with all six cysteines alkylated by IA
(m/z	 6 57;m/z 7661.53 for unmodified peptide, Figs. 4A
and 5). STZ treatment led to the appearance of several new
species with a lower m/z suggesting that some cysteines were
modified by the STZ treatment and were not available for the
reaction with IA. Two key species were identified, one species
with four alkylated cysteines and the remaining two cysteines in
the form of a disulfide and one species with two alkylated cys-
teines and two disulfides (Fig. 4B). In addition, we identified
another species with three alkylated cysteines, one disulfide,
and one cysteine in the form of a cysteinyl radical. As cysteinyl
radicals could be further oxidized to sulfenic acids and/or sul-
fonic acids, which could be an irreversible form of TRPA1 acti-
vation (32), an experiment was performed where the sulfenic
acid trap dimedone was added to the reactionmixture contain-
ing the peptide and STZ.After 75min, the reactionmixturewas
analyzed to reveal the presence of dimedone-labeled peptide
confirming that sulfenic acids are formed during STZ-induced
cysteine oxidation (Figs. 4C and 6). To identify the exact posi-
tion of these modifications, MS/MS analysis of the peaks was
performed. The data are suggestive of disulfides being formed
between Cys-621 and Cys-633 and between Cys-641 and Cys-
651 (Fig. 4D and Table 1). The presence of disulfides, cysteinyl
FIGURE 3. STZ stimulates TRPA1. A, concentration-dependent [Ca2]i
increases evoked by STZ in mTRPA1 CHO cells loaded with Fura-2. Data are
the mean percentages  S.E. (n 	 168–648 cells per concentration) of the
maximal response amplitude produced by a subsequent challengewith AITC
(50M). B, concentration-dependent [Ca2]i responses evokedby STZ inDRG
neurons.Datapoints showthepercentageofAITC-sensitiveneurons that also
responded to an initial challenge with STZ (n	 117–236 AITC-sensitive DRG
neurons per concentration). Application of STZ (0.5 mM) stimulated [Ca2]i
responses in TRPA1-positive (AITC-sensitive) neurons cultured from Trpa1/
mice (C) but waswithout effect on [Ca2]i in neurons from Trpa1
/mice (D).
Fura-2 emission intensity ratio is indicated by F340/380. STZ (1 mM)-induced
current responses recorded frommTRPA1 CHO cells (E, n	 5), AITC-sensitive
DRGneurons (F, representative ofn	4), andexcised inside-out patches from
TRPA1 CHO cells (G). In G, the top trace indicates a lack of single channel
activity prior to STZ application; the bottom trace shows STZ-evoked channel
activity. The closed and open channel current levels are indicated by c and o
(the trace is representative of n 	 3 patches). Currents were recorded at a
holding potential of60 mV. H, TRPA1 currents evoked by STZ in CHO cells
were reversibly inhibited by HC030031 (50 M, representative of n 	 5). I,
current-voltage relationship of TRPA1 current evoked by STZ in the presence
and absence of HC030031 (50 M). Experiments with HC030031 were per-
formed under Ca2-free conditions.
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radicals, and sulfenic acids implies that STZ decomposition
products act as thiol oxidizing agents, which could be themech-
anism by which STZ activates TRPA1 channels.
In a separate experiment, we collected DRG from untreated
control mice and from STZ-treatedmice 1 and 24 h after injec-
tion to assess whether STZ (180 mg/kg) treatment produced
TRPA1 oxidation in vivo (Fig. 4E). TRPA1 protein was purified
fromDRGs and analyzed by amodified biotin-switch assay (25).
The observed basal level of disulfides present in TRPA1 is in
good agreement with our recent findings (25). We noticed an
obvious increase in the fluorescence labeling of TRPA1 purified
from mice 1 and 24 h after STZ treatment, compared with
TRPA1 purified from ganglia collected from untreated mice
(Fig. 4E). This observation demonstrates that treatment with
STZ acutely increases the content of oxidized thiols in TRPA1
in vivo, an effect that lasts for at least 24 h (Fig. 4E).
Previous studies showed that decomposition of STZ leads to
formation of both superoxide andnitric oxide (NO) (33–35). As
these two react in a diffusion-controlled manner to form
peroxynitrite (36), which is known to oxidize cysteines forming
sulfenic acid and/or disulfides (37), we examined a direct reac-
tion of STZ with cysteines. Decomposition of STZ in buffered
solution (pH 7.4) was monitored by time-resolved ESI-TOF-
MS. Our data clearly show that STZ spontaneously decom-
poses with time as observed by the drop of the STZ parent ion
([STZNa],m/z 288.08, Fig. 7A). When STZ was incubated
with cysteine for 15, 30, and 60min and the total amount of free
thiols assessed by Ellman’s reaction, an obvious time-depen-
dent decrease in free thiols was observed (Fig. 7, B and C). The
possibility that peroxynitrite might be formed was tested using
the standard fluorescence sensor for peroxynitrite, dihydrorho-
damine 123. As shown in Fig. 7D, incubation of dihydrorhod-
amine 123 with STZ led to formation of fluorescent rhodamine
123. In addition, formation of dityrosine, an oxidation product
of the reaction of peroxynitrite with tyrosine, was monitored
by spectrofluorometry. Fig. 7E confirms that dityrosine was
formed when STZwas incubated with tyrosine, suggesting that
peroxynitrite is indeed the active compound. Furthermore, it
was not possible to detect free superoxide using the superoxide-
specific fluorescence sensor hydroethidine, an observation that
provides additional support for peroxynitrite formation from
spontaneous STZ decomposition (data not shown). We also
examined the possible involvement of superoxide andH2O2 for
the TRPA1 agonist activity of STZ using the superoxide dismu-
tase mimetic MnTM-PyP-Cl5 (38). As shown in Fig. 7F,
MnTM-PyP-Cl5 (10 M) did not reduce [Ca2]i responses
evoked by 0.5 mM STZ in mTRPA1 CHO cells, suggesting that
superoxide is not the activator of TRPA1,which is in agreement
with the lack of hydroethidine oxidation. MnTM-PyP-Cl5 may
also possess moderate catalase activity (39). If H2O2 was
responsible for the STZ-induced TRPA1 activation, the treat-
ment with MnTM-PyP-Cl5 should inhibit this effect. The
mimetic indeed inhibited [Ca2]i increases stimulated byH2O2
alone (Fig. 7G), but it had no effect on STZ-induced responses,
further strengthening the evidence for peroxynitrite rather
than a superoxide/H2O2 pathway.
The rate of STZ decomposition andNO release can be accel-
erated by UV irradiation (33). Brief UV irradiation (10 s, 380
nm) during applications of STZ at concentrations (100–200
M), which on their own failed to elicit macroscopic currents in
hTRPA1-expressing HEK293 cells, rapidly stimulated large
TRPA1 currents (Fig. 8, A–D). More extended periods of irra-
diation with 380 nm light (60 s) evoked TRPA1 currents in the
absence of other stimuli but with slower onset and with signif-
FIGURE 4. STZ oxidizes critical cysteine residues of TRPA1 N terminus. A,MS spectrum of the TRPA1 peptide used in the study. B,MS spectrum of peptide
(50M) treatedwithSTZ (500M) for 75min.After the reaction, the remaining free cysteineswereblockedwith IA.C,dimedone trappingof sulfenic acid formed
in the reaction of STZ and the peptide. AU, arbitrary units.D, actual positions of the two disulfide bonds formedwhen TRPA1 peptide was exposed to STZ. The
positions of critical cysteines are indicated by the numbers given in parentheses. Cysteines marked yellow are found to form intramolecular disulfides. The
cysteine residue,which also forms sulfenic acid and is observed inMS analysis as labeledwith dimedone, ismarked green. Formore details see Figs. 5 and 6 and
Table 1. E, TRPA1 protein purified fromDRGs collected from controlmice (0 h) contained a basal level of disulfides. STZ increased the content of oxidized thiols
in TRPA1 protein at 1 and 24 h after injection. The lower panel indicates the total protein load.
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icantly smaller amplitudes than in combination with STZ (Fig.
8C), in agreement with an earlier study (40).
Functional Importance of N-terminal Cysteine Residues—We
next examined HEK 293t cells expressing hTRPA1 using
[Ca2]i measurements to confirm that STZ also activates the
human TRPA1 channel. Application of STZ (50 M, 30 s)
evoked robust increases in [Ca2]i in 52.9% of hTRPA1-posi-
tive cells (expression confirmed using the nonelectrophilic
hTRPA1 agonist carvacrol (250 M, 30 s, Fig. 9, A and G). Nei-
ther STZ (1 mM) nor carvacrol (250 M) evoked [Ca2]i
responses in untransfected HEK 293t cells. The TRPA1 antag-
onist HC030031 (50 M) completely blocked STZ-induced
responses in hTRPA1 cells (Fig. 9, B and G). However, we
noticed an immediate [Ca2]i response after washout of
HC030031, suggesting that the STZ-mediatedmodifications of
hTRPA1 were sustained and not immediately reversible (Fig.
9B). The presence of a stoichiometric excess of dithiothreitol
(DTT) provides thiol groups that may scavenge reactive STZ
decomposition products such as peroxynitrite. The presence of
5 mM DTT abolished hTRPA1 activation by 50 M STZ (Fig. 9,
C andG), without affecting the basal [Ca2]i in cells before STZ
stimulation (p	 0.6).
We examined the agonist activity of STZ on HEK 293t cells
transfected with the hTRPA1 C621S/C641S/C665S mutant
(hTRPA1-3C) to determine the functional importance of the
cysteine residues identified in the mass spectrometry studies
above (7). These three cysteine residues have previously been
identified as critical for gating of the human TRPA1 channel by
electrophilic compounds, with channels carrying the triple
mutation exhibiting a very substantially reduced responsive-
FIGURE5.Speciationof thepeaksobservedbyMSanalysisofSTZ-treated
TRPA1 peptide. A, observed spectrum. B–E, peak assignment based on the
isotopic distribution prediction. Upper panels (black) correspond to the mea-
sured peaks, and the lower panels (red, blue, green, and pink) represent the
isotopic distribution prediction for the modification marked on each panel,
obtained by the Data Analysis software (Bruker Daltonics).
FIGURE 6.Peakassignments for theSTZdimedone-treatedTRPA1pep-
tide.A andB, upper figure (black) corresponds to themeasuredpeaks, and the
lower figure (red and green) represents the isotopic distribution prediction for
the modification marked on each panel, obtained by the Data Analysis soft-
ware (Bruker Daltonics).
TABLE 1
Rationale for the disulfide bond assignments
Peptide fragments were detected in theMS/MS analysis of the STZ-treated peptide
and/or STZ dimedone-treated peptide. Cysteine residues that form disulfides are
marked blue; the cysteine residue that is oxidized to sulfenic acid is marked green,
and the cysteine residue modified by IA is marked red.
* Data were calculated for unmodified peptide.
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ness to electrophilic agonists (7). STZ (50 M) only induced
[Ca2]i increases in a relatively small proportion of
hTRPA1-3C cells (12.1%), whereas higher concentrations of
STZ (750M) evoked intense responses in 49.2% cells (Fig. 9,D
and E). The observation that the effect of the triple cysteine
mutant was surmountable indicates that STZmust target other
amino acid residues in addition to Cys-621, Cys-641, and Cys-
665. Peroxynitrite liberated from STZ could oxidize intracellu-
lar glucose leading to the formation of products that are shown
to modify lysine residues to form N-(carboxymethyl)lysine
(41). Lysine 710, together with the three cysteines, has been
shown to be important for the agonist activity of AITC (7). In
keeping with such a mechanism, cells expressing the hTRPA1
C621S/C641S/C665S/K710R (hTRPA1-3CK) quadruple mu-
tant were completely insensitive to a high concentration (1mM)
of STZ (Fig. 9F). This observation confirms earlier reports that
Lys-710 is specifically targeted by TRPA1 agonists that act
through electrophilic modification (7). Importantly, all
hTRPA1-3CK cells did respond to the noncovalent hTRPA1
agonist carvacrol, so although it is possible that some of the loss
of function seen with the quadruple mutation is due to struc-
tural changes of the channel protein, the channel remains func-
tional and able to respond to some agonists.
Discussion
Here, we have demonstrated that STZ stimulates TRPA1 in
vivo and in vitro. STZ evokes TRPA1-dependent polymodal
hyperalgesia after topical administration but acute sensory loss
after systemic administration. In vitro, we show that STZ stim-
ulates TRPA1 in cultured DRG neurons, cell lines, and excised
membrane patches. Spontaneous decomposition of STZ gener-
ates the oxidant peroxynitrite, and we show that STZ treatment
leads to oxidation of TRPA1 cysteine residues in vivo and in vitro.
STZ Targets TRPA1 in Vivo—TRPA1 has been identified as a
potential pharmacological target both for disease modification
and for treatment of the pain and sensory abnormalities asso-
ciated with diabetic neuropathy (14, 15). These conclusions
were based on the observations that TRPA1 inhibition reduces
the loss of epidermal nerve fibers and inhibits the mechanical
hyperalgesia seen in STZ-treated diabetic rats. A second line of
work further implicated TRPA1 as an effector molecule in dia-
betic sensory neuropathy. The electrophilic glucose metabolite
methylglyoxal, which is produced endogenously during hyper-
glycemia, and reactive oxygen species and lipid peroxidation
FIGURE 7. STZ decomposes spontaneously to give a peroxynitrite-like product. A, time-resolved MS spectrum of the parent STZ ion, [STZ Na] at m/z
288.08. B and C, STZ-induced oxidation of cysteine thiols. Cysteine (40M) was incubatedwith STZ (400M), and the amount of free thiols was determined by
Ellman’s reagent (5,5-dithiobis(nitrobenzoic acid) (DTNB)) at different time points. The time-dependent decay of the 412-nm product indicates STZ-induced
oxidationof thiols (n	 3 experiments, data points aremean S.E.).D, STZ-inducedoxidationof dihydrorhodamine to the fluorescent product, rhodamine 123
(n	 3 experiments, data points are mean S.E.). E, fluorescence spectra of tyrosine incubated with STZ, indicating the formation of dityrosine. Black is the
control spectrumof1mMtyrosinebefore theadditionof STZ.Red topink, spectra collectedatdifferent timepoints after theadditionof 10mMSTZ.F, superoxide
dismutasemimeticMnTM-PyP-Cl5 (10M) did not reduce STZ (0.5mM)-evoked [Ca
2]i responses in TRPA1 CHO cells (p 0.05, n	 4 coverslips with at least 20
cells).G,MnTM-PyP-Cl5 inhibits H2O2 evoked [Ca
2]i responses in CHO cells expressingmTRPA1 (n	 3 experiments, each run in triplicatewells). Data points in
G are the mean S.E. from one representative experiment. a.u., arbitrary units.
FIGURE 8. Irradiation with UV light (380 nm) enhances STZ-induced
inward currents. A, STZ (100 M) induced immediate inward currents in
hTRPA1-transfectedHEKcells,whencellswere irradiatedwith380nmfor 10 s.
No inward currents were recorded by a brief application of STZ 100 M (20 s)
alone. B, continuous irradiation with UV light (380 nm, 60 s) activates TRPA1,
butwitha sloweronset and toa lesser extent (C) than in combinationwithSTZ
100 M (**, p 
 0.004, Mann-Whitney U test, n 	 6). D, combination of STZ
(200 M) and fluorescent light (380 nm, 10 s) leads to immediate inward cur-
rents in TRPA1-expressing HEK cells. Carv, carvacrol.
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products, which also occur at increased levels in diabetes, evoke
pain and hypersensitivity by activation of TRPA1 (14, 16–18,
42). TRPA1 thus appears to play a central role both for the
development of sensory diabetic neuropathy in STZ models
and as a molecular pronociceptive target for metabolites
formed in diabetes during hyperglycemic episodes.
Here, we show that activation of TRPA1 by topical adminis-
tration of very low doses of STZ elicits mechanical and thermal
hypersensitivities in vivo. These STZ-induced hypersensitivi-
ties are lost in TRPA1-null mice and completely inhibited by
the selective TRPA1 antagonist AP18 in wild type mice, dem-
onstrating that peripheral activation of TRPA1 is responsible
for the acute pronociceptive response. Systemic administration
of STZ produced an acute sensory loss to cold and mechanical
stimulation in wild type animals. Mechanical and cold hypoal-
gesia was established within an hour of STZ administration,
while themice developed hyperglycemia around day 3.We also
show that the onset of hypoalgesia is associated with oxidation
of TRPA1 cysteine residues in vivo (at 1 and 24 h after STZ).
Because the STZ-induced hypoalgesia appeared before the
onset of hyperglycemia, our results suggest that an effect of STZ
on TRPA1 explains the rapid appearance of sensory behavioral
changes. STZ treatment produces a qualitatively different
behavioral profile in rats and mice. Rats generally develop
hyperalgesia after STZ, whereas mice, in agreement with this
report, develop hypoalgesia (5). However, it is not likely that
species differences in the TRPA1 sequence are responsible for
this discrepancy. TRPA1 is highly conserved between rats and
mice (97% identity), and the residues previously proposed to be
important for channel activation are identical (6). Previous
reports of thermal andmechanical hyperalgesia, which develop
both in hyperglycemic and normoglycemic STZ-treated rats,
therefore support our behavioral findings (43, 44). In this study,
the magnitudes of the sensory deficits were similar for at least
10 days following STZ administration. This observation sug-
gests that it would be difficult to distinguish sensory abnormal-
ities produced directly by STZ from those that develop as a
consequence of the ensuing diabetic neuropathy. In contrast to
the sensory loss observed in wild type mice, STZ treatment
produced hypersensitivity to mechanical, heat, and cold stimu-
lation within 24 h in Trpa1/mice. The STZ-induced hyper-
sensitivities observed in TRPA1-nullmice suggest that STZ can
evoke complex sensory changes but that TRPA1-mediated sen-
sory loss is the dominant mechanism in wild type animals.
Oxidative stress and an increased production of reactive car-
bonyl compounds such as methylglyoxal are prominent factors
leading to the development of diabetic neuropathy and other
diabetic complications (45–47). Methylglyoxal, oxidants, and
electrophilic agents formed during oxidative stress all stimulate
TRPA1 (14, 16–18), and earlier studies have demonstrated that
inhibition of TRPA1 reduces or prevents both the loss of intra-
epidermal nerve fibers and the behavioral manifestations of
STZ-induced diabetic neuropathy in the rat (14, 15). In models
of STZ-induced diabetes, TRPA1 is thus targeted both acutely
by STZ, as demonstrated here, and by glucose metabolites dur-
ing the later phase of diabetic neuropathy.
Topical administration of TRPA1 agonists, e.g. to the paw,
evokes pain or hyperalgesia (12, 26, 48, 49). In contrast, intrathe-
cal administration of TRPA1 or TRPV1 agonists or systemic
administration of TRPV1 agonists (TRPV1 is expressed in the
majority of TRPA1 containing sensory neurons) results in anal-
gesia or hypoalgesia (28, 50–52). Persistent stimulation of
TRPV1 leads to desensitization or even damage to central or
peripheral terminal (51, 53), which has also been proposed to
be the consequence of persistent stimulation of TRPA1 (14).
In addition, depolarization of the central terminals of noci-
ceptive neurons by intrathecal administration of TRPA1 or
TRPV1 agonists produce analgesia through mechanisms
akin to depolarization block or presynaptic inhibition (28,
50, 54). Our observations following topical intraplantar
(hyperalgesia) and systemic intraperitoneal injections (hypoal-
gesia) of STZ are therefore in excellent agreement with earlier
observations implicating TRPA1 activation with the observed
behavioral changes.
FIGURE9.STZactivationofTRPA1 involvesmodificationof intracellular cysteine residues.STZ (50M) stimulated [Ca2]i responses inhTRPA1-expressing
HEK293 cells loadedwith Fura-2 (A). Application of the TRPA1 antagonist HC030031 inhibited [Ca2]i responses, but amarked rebound increase in [Ca
2]iwas
seen after the antagonist was removed (B). The reducing agent dithiothreitol (5 mM) abolished STZ-evoked [Ca2]i responses (C). In HEK 293t cells transfected
with the human TRPA1, the C621S/C641S/C665S mutant channel (3C) [Ca2]i responses to stimulation with STZ (50 M) were strongly reduced (D). Higher
concentrations of STZ (750 M) still produced [Ca2]i responses in cells expressing the triple cysteine mutant channel (E). STZ (1 mM) failed to induce [Ca
2]i
responses in cells expressing the hTRPA1-3C/K710R (3CK) mutant channel (F). Application of carvacrol (250 M, for 30 s) was used as a positive control to
confirmchannel function inA–F.G,quantificationof the resultspresented inA–F. Thebar chartdemonstrates theareaunder the curve (AUC) of the fluorescence
ratio signals 60 s following STZ stimulation in wild type hTRPA1, the mutant hTRPA1-3C, and hTRPA1-3CK cells. The data in A–G show the mean responses of
n	 120–448 cells, S.E. have been omitted in A–F for clarity. ***, p
 0.001 compared with control; ###, p 0.001 compared with hTRPA1-3C 50 M STZ; or
analysis of variance followed by HSD post hoc test.
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Mechanism of Action—In this report we demonstrate that
STZ stimulates TRPA1 at concentrations below those thought
to be required to kill cultured pancreatic-cells in vitro (2mM
(55, 56)). STZ stimulates TRPA1 in excisedmembrane patches,
which indicates that channel activation occurs through a direct
membrane delimited mechanism. Our studies of the spontane-
ous decomposition of STZ provide strong evidence for forma-
tion of peroxynitrite and directmodification of the TRPA1 pro-
tein. In agreement with peroxynitrite liberation mediating
TRPA1 stimulation by STZ, we found that STZ covalently
modified an N-terminal peptide by oxidizing several cysteine
residues both to disulfides and sulfenic acid (see Scheme 1). In
vivo, STZ treatment increased the content of oxidized thiols
(cysteine residues) in TRPA1 protein purified from DRGs. It
should be noted that the STZ concentrations achieved in vivo
following intraperitoneal injections of STZ (180 mg/kg, 0.68
mmol/kg) are likely to be comparable with the 500M, which
was used to modify cysteine residues in our MS experiments.
Functional analysis of TRPA1 mutants demonstrated that
the cysteine residues modified by incubation with STZ are also
important for the agonist activity of STZ. In addition, our stud-
ies suggest a role for Lys-710 in STZ-induced channel activa-
tion. Although peroxynitrite does not react with lysine directly,
it has been shown that it does oxidize glucose and that oxida-
tion products formed in this reaction modify lysine leading to
the formation of N-(carboxymethyl)lysine, one of the proto-
typical advanced glycation end products (41). This reaction is
also thought to be of importance in diabetic neuropathy (57).
Although high concentrations of STZ could still activate the
triple cysteinemutant channel (C621S, C641S, andC665S), this
agonism was lost in channels containing the additional K710R
mutation. This could either suggest a reaction involving Lys-710
or, perhapsmore likely, an indirect influence of this residue on the
sensitivity to oxidants and electrophilic agents (58).
There are two major pathways that could account for the
observed cysteine oxidation products (Scheme 1). Decomposi-
tion of STZ could lead to superoxide and finally H2O2 (Scheme
1-i) (35, 59), which is a two-electron oxidant known to activate
TRPA1 channels (17). However, STZ decomposes to give both
NO and superoxide (33–35, 59), which are known to react in a
diffusion-controlled manner to give peroxynitrite, a powerful
oxidant that could produce all the cysteine modifications that
we observed, i.e. cysteinyl radical, sulfenic acid, and disulfides
(Scheme 1-ii) (37). Under physiological conditions, i.e. in the
absence of oxidative stress, disulfides could be reduced by the
reductive cellular environment or by the action of disulfide
reductases. In contrast, cysteine residues oxidized further to
sulfenic acids would be irreversibly modified. Our experiments
with the TRPA1 antagonist HC030031 in hTRPA1 HEK cells
showed that although this compound inhibited STZ-evoked
responses completely, a sudden Ca2-influx response was evi-
dent whenHC030031was removed from the extracellular solu-
tion several minutes after the removal of STZ, demonstrating
that the agonist effect of STZ is not rapidly reversible. In vivo,
local co-administration of the TRPA1 antagonist AP18 to-
gether with STZ completely inhibited the STZ-evoked hyper-
sensitivity for 3 h, but thereafter the mechanical hyperalgesia
developed to the same level as in mice that received vehicle
instead of AP18, presumably reflecting tissue clearance of the
antagonist. Finally, administration of STZ oxidizedTRPA1 cys-
teine residues in vivo, an effect that was evident for at least 24 h.
These observations are compatible with slowly reversible (dis-
ulfides) or irreversible (sulfenic acids) modification of TRPA1,
resulting in sustained channel activation. It is possible that STZ,
methylglyoxal, H2O2, nitroxyl (HNO) (16–18, 25), and other
agents that stimulate TRPA1 through disulfide formation pro-
duce a sustained mode of TRPA1 activation. Persistent TRPA1
channel activity may contribute to the development of long
lasting sensory abnormalities seen in STZ-treated diabetic (14)
and nondiabetic (43) animals, but also in otherwise healthy
mice with elevated methylglyoxal levels (16, 19). Formation of
dityrosine and oxidation of dihydrorhodamine, as well as unde-
tectable superoxide levels, suggest that peroxynitrite is themost
probable active principle for STZ-induced TRPA1 stimulation.
Treatment with a peroxynitrite decomposition catalyst for 3
weeks, starting 3 weeks after diabetes induction with STZ, has
previously been shown to counteract the development of sen-
sory neuropathy in STZ-treated mice (60). Peroxynitrite may
therefore contribute both to the acute effects of STZ and the
later development of diabetic sensory neuropathy. The results
from our detailed characterization of STZ decomposition sup-
port an earlier demonstration that STZ can produce nitric
oxide under certain conditions (33). Nitric oxide reacts very
slowly with thiols (61, 62), and accordingly, TRPA1 is resistant
even to high concentrations of the NO donor diethylamine
SCHEME 1. Two possible pathways for STZ decomposition, which could lead
to TRPA1 activation, are as follows: (i) STZ decomposes to give superoxide,
which forms H2O2, or (ii) STZ decomposes to give both NO and superoxide,
which react immediately to give peroxynitrite.
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NONOate (25). It is therefore unlikely that nitric oxide itself
contributes to the agonist activity of STZ. The rate of STZ
decomposition is increased by UV light, and in our measure-
ments, irradiation with 380 nm produced a marked potentia-
tion of the effects of STZ. In the presence of UV irradiation,
brief applications of modest concentrations of STZ elicited
large, almost instantaneous, TRPA1 currents, and it is tempting
to speculate that both NO and superoxide are released from
irradiated STZ, with diffusion-controlled, rapid formation of
peroxynitrite as a consequence. TRPA1 can itself be activated
by UV light and photosensitizing agents (40), and we did
observe small, slowly developing currents in response to con-
tinuous illumination with 380 nm, but these responses were
much smaller than those observed in the presence of STZ.
Conclusions—Here, we report the identification of TRPA1 as
a molecular target for STZ, which may explain the rapid onset
of sensory abnormalities seen in studies of STZ-induced dia-
betic sensory neuropathy before glucose levels are elevated.We
demonstrate a TRPA1-dependent, rapid, and sustained loss of
cold and mechanical sensitivity following systemic STZ treat-
ment. The acute sensory abnormality produced by systemic
STZ may not be readily distinguished from hypoalgesia devel-
oping later as a consequence of diabetic neuropathy. This
report further provides new details of the chemical decompo-
sition of STZ and identifies peroxynitrite-mediated oxidation
of TRPA1 as an effectormechanism for STZ in vivo and in vitro.
In studies of STZ-evoked diabetic neuropathy, TRPA1 may be
targeted both directly by STZ and later by the oxidative stress
and formation of electrophilic glucose metabolites such as
methylglyoxal associated with hyperglycemia. Direct activation
of TRPA1 seriously complicates the interpretation of STZ-in-
duced models of diabetic sensory neuropathy, and our results
argue that more refined models of diabetic neuropathy should
replace the use of STZ.
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